Skip to main content
    B

    Bone Biologics Corp (BBLG)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.29
    -0.03 (-9.50%)

    Market Cap: $1.10M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Bone Biologics Corp (BBLG) Financials: Revenue, Profit and Cash Flow

    Updated Oct 26, 2026. Financial statements from company filings, amounts in US dollars.

    Bone Biologics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$3.11M, operating cash flow was -$2.69M and free cash flow was -$2.69M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$617.65K.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $3.23M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Cost of revenueN/AN/A$0$0$0$0$50$96$96$700
    Gross profitN/AN/A$0$0$0$0-$50-$96-$96-$700
    Research and development$1.06M$2.13M$6.91M$1.58M$82.04K$340.67K$1.10M$104.49K$1.19M$11.60M
    Operating income-$3.23M-$4.22M-$9.43M-$3.67M-$1.10M-$825.01K-$2.45M-$2.79M-$2.63M-$20.41M
    Net income-$3.11M-$4.11M-$8.95M-$1.48M-$1.61M-$1.82M-$3.42M-$4.43M-$7.05M-$25.88M
    EBITDA-$3.11M$107.16K$479.30K-$752.91K-$803.98K-$825.01K-$2.45M-$2.79M-$2.63M-$20.41M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$666.34K-$808.11K-$805.05K-$733.11K-$715.27K-$748.08K-$1.04M-$1.55M-$951.02K-$809.66K-$903.54K-$1.16M
    Net income-$617.65K-$773.70K-$765.99K-$684.64K-$666.74K-$740.52K-$1.02M-$1.52M-$941.00K-$783.73K-$865.97K-$1.55M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $5.33M were 91.9% of total assets of $5.80M, against total liabilities of $418.59K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$5.80M$3.86M$3.74M$8.50M$6.68M$0$30.83K$1.04M$795.66K$973.09K
    Current assets$5.80M$3.86M$3.74M$8.50M$6.68M$0$30.83K$1.04M$795.51K$700.90K
    Cash and equivalents$5.33M$3.33M$3.03M$7.54M$6.68M$0$24.14K$955.37K$690.28K$620.38K
    Total liabilities$418.59K$377.71K$831.40K$2.55M$99.91K$13.69M$11.90M$9.64M$9.19M$9.61M
    Short-term debtN/AN/AN/AN/AN/A$11.72MN/A$9.00M$0$1.20M
    Long-term debtN/AN/AN/AN/AN/AN/A$11.32M$0$8.23M$6.28M
    Shareholder equity$5.38M$3.48M$2.91M$5.95M$6.58M-$13.69M-$11.87M-$8.60M-$8.40M-$8.36M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$6.43M$4.44M$4.98M$5.80M$6.35M$7.00M$3.16M$3.86M$4.07M$3.19M$3.84M$3.74M
    Total liabilities$480.77K$512.02K$309.39K$418.59K$334.28K$406.14K$251.16K$377.71K$273.40K$284.51K$164.63K$831.40K
    Cash and equivalents$6.09M$4.03M$4.53M$5.33M$6.05M$6.64M$2.75M$3.33M$3.57M$2.33M$3.23M$3.03M
    Shareholder equity$5.95M$3.92M$4.67M$5.38M$6.02M$6.60M$2.91M$3.48M$3.79M$2.91M$3.67M$2.91M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$2.69M-$4.12M-$9.56M-$3.57M-$1.23M-$426.93K-$3.25M-$4.10M-$3.33M-$7.33M
    Capital expenditures$0$5$0$0$0$0$0$0$0$0
    Free cash flow-$2.69M-$4.12M-$9.56M-$3.57M-$1.23M-$426.93K-$3.25M-$4.10M-$3.33M-$7.33M
    Dividends paidN/A$3.21MN/AN/AN/AN/AN/A$0$0$0
    Financing cash flow$4.70M$4.42M$5.04M$4.43M$7.90M$402.79K$2.32M$4.37M$3.40M$6.83M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$532.27K-$518.44K-$804.28K-$714.76K-$591.38K-$458.88K-$926.13K-$1.35M-$572.16K-$895.87K-$1.30M-$2.02M
    Capital expenditures$0$0$0$5$0$5$5$3$0$0$0$0
    Free cash flow-$532.27K-$518.44K-$804.28K-$714.77K-$591.38K-$458.88K-$926.13K-$1.35M-$572.16K-$895.87K-$1.30M-$2.02M
    Last 12 quarters

    Frequently Asked Questions About BBLG

    What is Bone Biologics' annual revenue?

    Bone Biologics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Bone Biologics profitable?

    No. Bone Biologics reported net income of -$3.11M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does BBLG generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$2.69M minus capital expenditures of $0 produced free cash flow of -$2.69M.

    How much debt does Bone Biologics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $5.33M.